Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Prospective, Placebo-Controlled, Crossover Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7)

NCT05159687 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT05159687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05159687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Prospective, Placebo-Controlled, Crossover Study of Atomoxetine in the Prevention of Vasovagal Syncope (POST7)
Lead sponsor
University of Calgary
Phase
Phase 3
Overall status
Recruiting
Start date
June 1, 2022
Completion date
September 30, 2027
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vasovagal syncope